SEARCH

SEARCH BY CITATION

References

  • Adlard P. A., Perreau V. M., Pop V. and Cotman C. W. (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J. Neurosci. 25, 42174221.
  • Ashe K. H. (2005) Mechanisms of memory loss in Abeta and tau mouse models. Biochem. Soc. Trans. 33, 591594.
  • Barghorn S., Nimmrich V., Striebinger A. et al. (2005) Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J. Neurochem. 95, 834847.
  • Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H. and De Strooper B. (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732742.
  • Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C. and Glabe C. (1992) Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546554.
  • Busciglio J., Lorenzo A. and Yankner B. (1992) Methological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol. Aging 13, 609612.
  • Cai X.-D., Golde T. E. and Younkin S. G. (1993) Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259, 514516.
  • Cai H. B., Wang Y. S., McCarthy D., Wen H. J., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233234.
  • Castaño E. M., Ghiso J., Prelli F., Gorevic P. D., Migheli A. and Frangione B. (1986) In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease β-protein. BBRC 141, 782789.
  • Chang L., Bakhos L., Wang Z. G., Venton D. L. and Klein W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-b oligomers and its application to Alzheimer’s disease drug candidate screening. J. Mol. Neurosci. 20, 305313.
  • Chapman P. F., White G. L., Jones M. W. et al. (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271276.
  • Chartier-Harlin M.-C., Crawford F. and Houlden H. (1991) Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844846.
  • Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. and Selkoe D. J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360, 672674.
  • Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J. and Ashe K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 7984.
  • Comery T. A., Martone R. L., Aschmies S. et al. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer’s disease. J. Neurosci. 25, 88988902.
  • Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C. Jr, Small G. W., Roses A. D., Haines J. L. and Pericak-Vance M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921923.
  • Dahlgren K. N., Manelli A. M., Stine W. B., Jr, Baker L. K., Krafft G. A. and LaDu M. J. (2002) Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32 04632 053.
  • De Jonghe C., Zehr C., Yager D., Prada C. M., Younkin S., Hendriks L., Van Broeckhoven C. and Eckman C. B. (1998) Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol. Dis. 5, 281286.
  • Demuro A., Mina E., Kayed R., Milton S. C., Parker I. and Glabe C. G. (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17 29417 300.
  • Deshpande A., Mina E., Glabe C. and Busciglio J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26, 60116018.
  • Dickson D. W., Crystal H. A., Bevona C., Honer W., Vincent I. and Davies P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285298.
  • Dineley K. T., Xia X. F., Bui D., Sweatt J. D. and Zheng H. (2002) Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277, 22 76822 780.
  • Dodart J. C., Bales K. R., Gannon K. S. et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat. Neurosci. 5, 452457.
  • Dudai Y. (2002) Molecular bases of long-term memories: a question of persistence. Curr. Opin. Neurobiol. 12, 211216.
  • Enya M., Morishima-Kawashima M., Yoshimura M. et al. (1999) Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am. J. Path. 154, 271279.
  • Esler W. P., Kimberly W. T., Ostaszewski B. L., Diehl T. S., Moore C. L., Tsai J. Y., Rahmati T., Xia W. M., Selkoe D. J. and Wolfe M. S. (2000) Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat. Cell Biol. 2, 428434.
  • Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M. and Holtzman D. M. (2002) Human and murine ApoE markedly alters Abeta metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 9, 305318.
  • Farris W., Schütz S., Cirrito J. et al. (2007) Loss of Neprilysin function promotes amyloid plaque formation and precipitates cerebral amyloid angiopathy. J. Neurosci. in press.
  • Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R. and Ihara Y. (1998) Quantitation of amyloid beta-protein (Abeta) in the cortex during aging and in alzheimers-disease. Am. J. Path. 152, 16331640.
  • Funato H., Enya M., Yoshimura M., Morishima-Kawashima M. and Ihara Y. (1999) Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Path. 155, 2328.
  • Gervais F., Paquette J., Morissette C. et al. (2006) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging, Epub ahead of print.
  • Geula C., Wu C. K., Saroff D., Lorenzo A., Yuan M. and Yankner B. A. (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4, 827831.
  • Gilman S., Koller M., Black R. S. et al. (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 15531562.
  • Glenner G. G. and Wong C. W. (1984) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. BBRC 120, 885890.
  • Goate A., Chartier-Harlin M.-C., Mullan M. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349, 704706.
  • Goldsbury C. S., Wirtz S., Muller S. A., Sunderji S., Wicki P., Aebi U. and Frey P. (2000) Studies on the in vitro assembly of Abeta1-40: implications for the search for a beta fibril formation inhibitors. J. Struct. Biol. 130, 217231.
  • Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A. and Klein W. L. (2003) Alzheimer’s disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. U. S. A. 100, 10 41710 422.
  • Gotz J., Chen F., Van Dorpe J. and Nitsch R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 14911495.
  • Gu Y., Misonou H., Sato T., Dohmae N., Takio K. and Ihara Y. (2001) Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J. Biol. Chem. 276, 35 23535 238.
  • Haass C., Schlossmacher M., Hung A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322325.
  • Harper J. D., Lieber C. M. and Lansbury P. T., Jr (1997a) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer’s disease amyloid-beta protein. Chem. Biol. 4, 951959.
  • Harper J. D., Wong S. S., Lieber C. M. and Lansbury P. T. Jr (1997b) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4, 119125.
  • Harper J. D., Wong S. S., Lieber C. M. and Lansbury P. T. (1999) Assembly of Abeta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer’s disease. Biochemistry 38, 89728980.
  • Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B. and Selkoe D. J. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 88768884.
  • Hepler R. W., Grimm K. M., Nahas D. D. et al. (2006) Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45, 15 157-15 167.
  • Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 38, 547554.
  • Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N. and Sato K. (2003) Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl Acad. Sci. U. S. A. 100, 63706375.
  • Hsia A. Y., Masliah E., McConlogue L., Yu G. Q., Tatsuno G., Ilu K., Kholodenko D., Malenka R. C., Nicoll R. A. and Mucke L. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 32283233.
  • Hsiao K. (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Experl. Gerontol. 33, 883889.
  • Huang S. M., Mouri A., Kokubo H. et al. (2006) Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281, 17 94117 951.
  • Huppert S. S., Ilagan M. X., De Strooper B. and Kopan R. (2005) Analysis of Notch function in presomitic mesoderm suggests a gamma-secretase-independent role for presenilins in somite differentiation. Dev. Cell 8, 677688.
  • Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C. L. and Beyreuther K. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22 90822 914.
  • Isaacs A. M., Senn D. B., Yuan M., Shine J. P. and Yankner B. A. (2006) Acceleration of amyloid beta-peptide aggregation by physiological concentrations of calcium. J. Biol. Chem. 281, 27 91627 923.
  • Jacobsen J. S., Wu C. C., Redwine J. M. et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. U. S. A. 103, 51615166.
  • Jarrett J. T., Berger E. P. and Lansbury P. T. Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 46934697.
  • Kakuda N., Funamoto S., Yagishita S., Takami M., Osawa S., Dohmae N. and Ihara Y. (2006) Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J. Biol. Chem. 281, 14 77614 786.
  • Katzman R. (1986) Alzheimer’s disease. N. Engl. J. Med. 314, 964973.
  • Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Kelly B. L. and Ferreira A. (2006) beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-d-aspartate receptors in hippocampal neurons. J. Biol. Chem. 281, 28 07928 089.
  • Kim H. J., Chae S. C., Lee D. K., Chromy B., Lee S. C., Park Y. C., Klein W. L., Krafft G. A. and Hong S. T. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 17, 118120.
  • Kirschner D. A., Inouye H., Duffy L. K., Sinclair A., Lind M. and Selkoe D. J. (1987) Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl Acad. Sci. U. S. A. 84, 69536957.
  • Klyubin I., Walsh D. M., Lemere C. A. et al. (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556561.
  • Kopan R. and Ilagan M. X. (2004) Gamma-secretase: proteasome of the membrane Nat. Rev. Mol. Cell Biol. 5, 499504.
  • Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R. and Van Broeckhoven C. (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 27, 686695.
  • Kuo W. L., Gehm B. D. and Rosner M. R. (1990) Cloning and expression of the cDNA for a Drosophila insulin-degrading enzyme. Mol. Endocrinol. 4, 15801591.
  • Lacor P. N., Buniel M. C., Chang L. et al. (2004) Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J. Neurosci. 24, 10 19110 200.
  • Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfribrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. U. S. A. 95, 64486453.
  • Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E., Yu J., Venton D. L., Krafft G. A., Finch C. E. and Klein W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595605.
  • Lashuel H. A., Hartley D. M., Balakhaneh D., Aggarwal A., Teichberg S. and Callaway D. J. (2002) New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer’s disease. J. Biol. Chem. 277, 42 88142 890.
  • Lazarov O., Robinson J., Tang Y. P., Hairston I. S., Korade-Mirnics Z., Lee V. M., Hersh L. B., Sapolsky R. M., Mirnics K. and Sisodia S. S. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701713.
  • Leissring M. A., Farris W., Chang A. Y., Walsh D. M., Wu X., Sun X., Frosch M. P. and Selkoe D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 10871093.
  • Lemere C. A., Maier M., Jiang L., Peng Y. and Seabrook T. J. (2006) Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 9, 7784.
  • Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352357.
  • Levy E., Carman M. D., Fernandez-Madrid I. J., Power M. D., Lieberburg I., Van Duinen S. G., Bots G. T. A. M., Luyendijk W. and Frangione B. (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 11241126.
  • Lewis J., Dickson D. W., Lin W. L. et al. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 14871491.
  • Li Y.-M., Xu M., Lai M.-T. et al. (2000) Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405, 689694.
  • Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E. and Rogers J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol. 155, 853862.
  • Maloney M. T., Minamide L. S., Kinley A. W., Boyle J. A. and Bamburg J. R. (2005) Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer’s disease. J. Neurosci. 25, 11 31311 321.
  • Mann D. M., Yates P. O. and Marcyniuk B. (1984) Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes. Neuropathol. Appl. Neurobiol. 10, 185207.
  • Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. and Schenk D. (2005) Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. U. S. A. 82, 42454249.
  • McLaurin J., Kierstead M. E., Brown M. E. et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801808.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860866.
  • Moechars D., Dewachter I., Lorent K. et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 64836492.
  • Morishima-Kawashima M. and Ihara Y. (1998) The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochem 37, 15 24715 253.
  • Motte J. and Williams R. S. (1989) Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol. 77, 535546.
  • Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K. and McConlogue L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Mueller-Steiner S., Zhou Y., Arai H. et al. (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron 51, 703714.
  • Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448452.
  • Nilsberth C., Westlind-Danielsson A., Eckman C. B. et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4, 887893.
  • Nybo M., Svehag S. E. and Holm Nielsen E. (1999) An ultrastructural study of amyloid intermediates in A beta 1-42 fibrillogenesis. Scand. J. Immunol. 49, 219223.
  • O’Hare E., Levine A. S., Semotuk M. T., Tierney K. J., Shephard R. A., Grace M. K. and Cleary J. (1996) Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone. Behav. Pharmacol. 7, 742753.
  • Oda T., Wals P., Osterburg H. H. et al. (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (Abeta 1-42) and forms slowly sedimenting Abeta complexes that cause oxidative stress. Exp. Neurol. 136, 2231.
  • Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y. and LaFerla F. M. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409421.
  • Olson M. I. and Shaw C. M. (1969) Presenile dementia and Alzheimer’s disease in mongolism. Brain 92, 147156.
  • Pike C. J., Walencewicz A. J., Glabe C. G. and Cotman C. W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311314.
  • Podlisny M. B., Ostaszewski B. L., Squazzo S. L., Koo E. H., Rydel R. E., Teplow D. B. and Selkoe D. J. (1995) Aggregation of secreted amyloid β-protein into SDS-stable oligomers in cell culture. J. Biol. Chem. 270, 95649570.
  • Prasher V. P., Farrer M. J., Kessling A. M., Fisher E. M., West R. J., Barber P. C. and Butler A. C. (1998) Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann. Neurol. 43, 380383.
  • Rebeck G. W., Reiter J. S., Strickland D. K. and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575580.
  • Richardson R. L., Kim E. M., Shephard R. A., Gardiner T., Cleary J. and O’Hare E. (2002) Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta (1-42) injections in the rat. Brain Res. 954, 110.
  • Roher A. E., Chaney M. O., Kuo Y.-M. et al. (1996) Morphology and toxicity of Abeta(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J. Biol. Chem. 271, 20 63120 635.
  • Rovelet-Lecrux A., Hannequin D., Raux G. et al. (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 2426.
  • Santacruz K., Lewis J., Spires T. et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476481.
  • Saunders A. M., Schmader K., Breitner J. C. S. et al. (1993) Apolipoprotein E ɛ4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 342, 710711.
  • Schenk D. B., Seubert P., Grundman M. and Black R. (2005) Abeta immunotherapy: lessons learned for potential treatment of Alzheimer’s disease. Neurodegener Dis. 2, 255260.
  • Schroeter E. H., Ilagan M. X., Brunkan A. L. et al. (2003) A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc. Natl Acad. Sci. U. S. A. 100, 13 07513 080.
  • SelkoeD. J. and SchenkD. (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545584.
  • Selkoe D. J., Abraham C. R., Podlisny M. B. and Duffy L. K. (1986) Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease. J. Neurochem. 146, 18201834.
  • Seubert P., Vigo-Pelfrey C., Esch F. et al. (1992) Isolation and quantitation of soluble Alzheimer’s β-peptide from biological fluids. Nature 359, 325327.
  • Shankar G. M., Townsend M., Walsh D. M., Selkoe D. J. and Sabatini B. L. (2007) Natural oligomers of the Alzheimer amyloid beta-protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules. J. Neurosci. in press.
  • Shoji M., Golde T. E., Ghiso J. et al. (1992) Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 258, 126129.
  • Siemers E. R., Quinn J. F., Kaye J. et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602604.
  • Snyder S. W., Ladror U. S., Wade W. S., Wang G. T., Barrett L. W., Matayoski E. D., Huffaker H. J., Krafft G. and Holzman T. (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67, 12161228.
  • Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 10511058.
  • Stenh C., Englund H., Lord A., Johansson A. S., Almeida C. G., Gellerfors P., Greengard P., Gouras G. K., Lannfelt L. and Nilsson L. N. (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 58, 147150.
  • Strittmatter W. J., Weisgraber K. H., Huand D., Dong L.-M., Salvesen G. S., Pericak-Vance M., Schmechel D., Saunder A. M., Goldgaber D. and Roses A. D. (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform specific effects and implications for late-onset Alzheimer disease. Proc. Natl Acad. Sci. U. S. A. 90, 80988102.
  • Suzuki N., Cheung T. T., Cai X.-D., Odaka A., Otvos L. Jr, Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid β protein secreted by familial amyloid beta-protein precursor (betaAPP717) mutants. Science 264, 13361340.
  • Tamagno E., Bardini P., Guglielmotto M., Danni O. and Tabaton M. (2006) The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 41, 202212.
  • Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A. and Katzman R. (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Annal. Neurol. 30, 572580.
  • Townsend M., Shankar G. M., Mehta T., Walsh D. M. and Selkoe D. J. (2006a) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477492.
  • Townsend M., Cleary J. P., Mehta T., Hofmeister J., Lesne S., O’Hare E., Walsh D. and Selkoe D. (2006b) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 60, 668676.
  • Van Nostrand W. E., Melchor J. P., Cho H. S., Greenberg S. M. and Rebeck G. W. (2001) Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276, 32 86032 866.
  • Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735741.
  • Vigo-Pelfrey C., Lee D., Keim P. S., Lieberburg I. and Schenk D. (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61, 19651968.
  • Walsh D. M., Lomakin A., Benedek G. B., Maggio J. E., Condron M. M. and Teplow D. B. (1997) Amyloid β-protein fibrillogenesis: Detection of a protofibrillar intermediate. J. Biol. Chem. 272, 22 36422 374.
  • Walsh D. M., Hartley D. M., Kusumoto Y., Fezoui Y., Condron M. M., Lomakin A., Benedek G. B., Selkoe D. J. and Teplow D. B. (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25 94525 952.
  • Walsh D. M., Tseng B. P., Rydel R. E., Podlisny M. B. and Selkoe D. J. (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10 83110 839.
  • Walsh D., Klyubin I., Fadeeva J., William K., Cullen W., Anwyl R., Wolfe M., Rowan M. and Selkoe D. (2002a) Naturally secreted oligomers of the Alzheimer amyloid beta-protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535539.
  • Walsh D. M., Klyubin I., Fadeeva J. V., Rowan M. J. and Selkoe D. J. (2002b) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552557.
  • Walsh D. M., Hartley D. M. and Selkoe D. J. (2003) The many faces of Abeta: structures and activity. Curr. Med. Chem – Immun., Endoc. Metab. Agents 3, 277291.
  • Walsh D. M., Townsend M., Podlisny M. B., Shankar G. M., Fadeeva J. V., Agnaf O. E., Hartley D. M. and Selkoe D. J. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25, 24552462.
  • Wang J., Dickson D. W., Trojanowski J. Q. and Lee V. M. (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp. Neurol. 158, 328337.
  • Wang H. W., Pasternak J. F., Kuo H. et al. (2002) Soluble oligomers of beta-amyloid(1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133140.
  • Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J. M., Masters C. L. and Beyreuther K. (1989) Identification, biogenesis and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 57, 115126.
  • Weidemann A., Eggert S., Reinhard F. B., Vogel M., Paliga K., Baier G., Masters C. L., Beyreuther K. and Evin G. (2002) A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41, 28252835.
  • Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G. and Ashe K. H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 18581867.
  • Whalen B. M., Selkoe D. J. and Hartley D. M. (2005) Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiol. Dis. 20, 254266.
  • White A. R., Reyes R., Mercer J. F., Camakaris J., Zheng H., Bush A. I., Multhaup G., Beyreuther K., Masters C. L. and Cappai R. (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842, 439444.
  • Wisniewski T., Ghiso J. and Frangione B. (1991) Peptides homologous to the amyloid protein of Alzheimer’s disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. BBRC 179, 12471254.
  • Wolfe M. S., Xia W., Ostaszewski B. L., Diehl T. S., Kimberly W. T. and Selkoe D. J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398, 513517.
  • Wu C. C., Chawla F., Games D., Rydel R. E., Freedman S., Schenk D., Young W. G., Morrison J. H. and Bloom F. E. (2004) Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc. Natl. Acad. Sci. USA 101, 71417146.
  • Xia W., Zhang J., Kholodenko D., Citron M, Podlisny M. B., Teplow D. B., Haass C., Seubert P., Koo E. H. and Selkoe D. J. (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 79777982.
  • Ye C. P., Selkoe D. J. and Hartley D. M. (2003) Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol. Dis. 13, 177190.
  • Zhao G., Mao G., Tan J., Dong Y., Cui M. Z., Kim S. H. and Xu X. (2004) Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J. Biol. Chem. 279, 50 64750 650.
  • Zhao L., Ma Q. L., Calon F. et al. (2006) Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9, 234242.